Spironolactone and SNRIs (Venlafaxine, Duloxetine): Interaction Guide

Print or save as PDFOpens the printable medication review sheet and your print dialog. No sign-up.

Do spironolactone and SNRIs interact?

No interaction is named in either direction. The spironolactone label's interaction content is built around potassium: it names potassium supplements, potassium-containing salt substitutes, ACE inhibitors and ARBs as combinations that can lead to severe hyperkalemia, and it also names NSAIDs, heparin and low molecular weight heparin, and trimethoprim as drugs that can raise potassium. It notes that spironolactone raises lithium levels and says to monitor them [1]. Venlafaxine and duloxetine are not among them.

On the other side, the Effexor XR (extended-release venlafaxine) label's clinically important interaction table covers MAOIs, other serotonergic drugs, drugs that interfere with hemostasis, CYP3A inhibitors and CYP2D6 substrates [2]. Spironolactone is not among them.

Is there a metabolic overlap?

Duloxetine is a moderate CYP2D6 inhibitor: desipramine AUC rose about three-fold when given with duloxetine 60 mg twice daily, and the label advises caution with tricyclics [3]. Spironolactone is rapidly and extensively metabolized to canrenone and to sulfur-retaining metabolites (7-alpha-thiomethylspironolactone and its 6-beta-hydroxy derivative), and the label names no cytochrome P450 enzyme and lists no CYP-based interactions [1]. Venlafaxine depends on CYP2D6 to make its active metabolite O-desmethylvenlafaxine, and its label advises considering lower doses of CYP2D6 substrates [2]. Neither label names spironolactone in a CYP interaction.

Sodium: where the label warnings overlap

The venlafaxine, desvenlafaxine and duloxetine labels all warn that hyponatremia can occur, in association with SIADH [2][4][3]. Spironolactone blocks aldosterone at the distal tubule, so more sodium and water are excreted [1], and its label lists hyponatremia and hypovolemia among reported adverse effects [1].

A retrospective cohort in the All of Us Research Program followed 17,439 people started on one of eight antidepressants as monotherapy. Hyponatremia, defined as a low sodium measurement or a recorded diagnosis, occurred in 0.87% within 30 days and 10.5% within 3 years. Against sertraline, duloxetine carried a hazard ratio of 1.37 (95% CI 1.19 to 1.58), the highest of the eight, while bupropion and paroxetine were lowest [5]. That cohort was antidepressant monotherapy, so it does not measure what happens when spironolactone is added.

Blood pressure can move in either direction

Spironolactone is labeled as add-on therapy for hypertension and for heart failure, and its label warns about hypotension and worsening renal function from excessive diuresis, particularly in salt-depleted patients and those taking ACE inhibitors or ARBs [1].

Venlafaxine's label describes dose-related rises in systolic and diastolic pressure and cases of sustained hypertension. In MDD trials at 75 to 375 mg/day, 19 of 705 patients (3%) met the sustained-hypertension definition, against 0.5% in generalized anxiety, 0.6% in social anxiety and 0.9% in panic disorder; across all studies, a rise of 15 mm Hg or more in supine diastolic pressure to 105 mm Hg or above occurred in 1.4% on venlafaxine versus 0.9% on placebo [2]. A 1998 meta-analysis of 3,744 depressed patients found the effect highly dose dependent and clinically significant only above 300 mg/day (immediate-release data), and it did not worsen blood pressure control in patients who already had high blood pressure [6].

Duloxetine behaves differently at usual doses. Adult placebo-controlled trials showed mean changes of +0.5 mm Hg systolic and +0.8 mm Hg diastolic, against falls of 0.6 and 0.3 mm Hg on placebo, with no significant difference in sustained elevated blood pressure. At 200 mg twice daily, about 3.3 times the maximum recommended dose, supine pressure rose 4.7 to 6.8 mm Hg systolic and 4.5 to 7 mm Hg diastolic [3]. The duloxetine label still says to check blood pressure before and periodically during treatment, and it carries warnings for orthostatic hypotension, falls and syncope [3]. The Effexor XR label says to monitor blood pressure before starting and regularly during treatment, and to control pre-existing hypertension first [2].

Potassium is spironolactone's own concern

The potassium issue belongs to spironolactone, not to the SNRI. Spironolactone can raise potassium, especially with impaired kidney function, potassium supplements, ACE inhibitors or ARBs. The current Aldactone label says to check serum potassium within 1 week of starting or changing the dose and regularly afterward, and to check potassium again when ACE inhibitor or ARB therapy is changed [1].

In healthy young women taking spironolactone for acne, 13 abnormal potassium values in 1,802 measurements gave a rate of 0.72%, compared with a 0.76% baseline rate in a comparison group of women taking and not taking spironolactone; 6 of the 13 abnormal values repeated normal [7]. That study excluded women with heart or kidney disease and those taking drugs that act on the renin-angiotensin system [7]. The label's potassium warnings are not limited to that group.

Does the acne dose change the picture?

Acne is not a labeled indication. The labeled uses are heart failure, hypertension, edema in cirrhosis or nephrotic syndrome, and primary hyperaldosteronism [1]. In the SAFA trial, 410 women with persistent facial acne were randomized to spironolactone (50 mg/day for six weeks, then 100 mg/day) or placebo; investigator-rated success at week 12 was 18.5% versus 5.6% [8].

Serotonin syndrome

Serotonin syndrome is a class warning on the SNRI labels. The Effexor XR label lists other serotonergic drugs as the partners that raise the risk: triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines and St John's wort, with MAOIs contraindicated [2]. Spironolactone is not on that list.